Asapiprant
产品说明书
 |
同义名 : | S-555739 |
| CAS号 : | 932372-01-5 | |
| 货号 : | A724929 | |
| 分子式 : | C24H27N3O7S | |
| 纯度 : | 99%+ | |
| 分子量 : | 501.55 | |
| MDL号 : | MFCD28902252 | |
| 存储条件： |
Pure form Sealed in dry, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Asapiprant is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM. Significant suppression of antigen-induced nasal resistance, nasal secretion, and cell infiltration in nasal mucosa was observed with asapiprant treatment. In addition, treatment with asapiprant suppressed antigen-induced asthmatic responses, airway hyper-responsiveness, and cell infiltration and mucin production in lung. Oral administration of Asapiprant to sheep at 1 and 3 mg/kg significantly suppresses the increase in nasal resistance by 82% and 92%, respectively. Asapiprant at 5 mg/kg suppresses Prostaglandin PGD2-induced nasal resistance by 86%. When orally administered 1 h before the antigen challenge in pigs, Asapiprant (3, 10, and 30 mg/kg) suppresses immediate airway response (IAR) by 52%, 57%, and 96%, and late airway response (LAR) by 67%, 50%, and 79%, respectively. Treatment with Asapiprant in rats at 10 mg/kg significantly reduces airway hyper-responsiveness (AHR), infiltration of inflammatory cells, and mucin production in bronchoalveolar lavage fluid (BALF), although treatment with Asapiprant at 0.1 mg/kg does not have a significant effect on any responses[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.99mL 0.40mL 0.20mL |
9.97mL 1.99mL 1.00mL |
19.94mL 3.99mL 1.99mL |
| 参考文献 |
|---|